Equities Analysts Offer Predictions for Evolus Q4 Earnings

Evolus, Inc. (NASDAQ:EOLS) – Equities researchers at HC Wainwright boosted their Q4 2026 earnings per share (EPS) estimates for Evolus in a research note issued on Thursday, November 5th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of $0.07 per share for the quarter, up from their prior estimate of $0.06. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Evolus’ FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.59 EPS.

EOLS has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evolus in a report on Friday, September 11th. BTIG Research increased their price objective on shares of Evolus from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Evolus Stock Performance

Shares of EOLS stock opened at $7.18 on Friday. Evolus has a 52 week low of $3.86 and a 52 week high of $9.31. The stock has a market capitalization of $475.24 million, a PE ratio of -15.28 and a beta of 1.38. The stock’s fifty day moving average is $7.66 and its 200-day moving average is $6.35.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 105,108 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the sale, the insider owned 499,592 shares in the company, valued at $4,516,311.68. The trade was a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 5.00% of the company’s stock.

Hedge Funds Weigh In On Evolus

Several large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its stake in shares of Evolus by 53.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 119,141 shares of the company’s stock valued at $953,000 after purchasing an additional 41,493 shares during the period. Inscription Capital LLC bought a new position in shares of Evolus in the 3rd quarter worth $108,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Evolus in the 3rd quarter worth $27,000. Profund Advisors LLC grew its stake in shares of Evolus by 412.0% during the third quarter. Profund Advisors LLC now owns 70,711 shares of the company’s stock worth $566,000 after purchasing an additional 56,901 shares during the period. Finally, Vise Technologies Inc. acquired a new stake in shares of Evolus during the third quarter worth $101,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc. is a medical aesthetics company focused on developing and commercializing treatments for cosmetic procedures. The company’s portfolio includes injectable products used by healthcare professionals to address facial lines and wrinkles and to enhance facial appearance. Its flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is a prescription botulinum toxin treatment for moderate to severe frown lines between the eyebrows in adults. Evolus also markets Evolysse, a line of hyaluronic acid dermal fillers designed for facial aesthetic treatments.